Plain-English translation of NCT07321951 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This is a Phase II trial testing a new injectable medication called SHR-1819 to treat moderate to severe atopic dermatitis — a chronic skin condition that causes intense itching, redness, and inflammation. Researchers want to see how well this medication works and whether it's safe. About 200 adults will be divided into groups receiving different doses to find the best treatment approach.
Atopic dermatitis is a painful, long-lasting skin condition that significantly affects quality of life, and many patients don't respond well enough to current treatments. This trial is testing whether this new medication could offer better relief for people with moderate to severe disease.
You likely qualify if…
You likely don't qualify if…
If you're accepted, you'll receive injections of the medication at different doses depending on which group you're assigned to. You'll visit the clinic regularly so doctors can monitor your skin, check how you're responding to treatment, and watch for any side effects. Throughout the study, you'll also use a daily moisturizing cream as part of the treatment plan.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Guangdong Hengrui Pharmaceutical Co., Ltd
Enrollment target
~200 participants
Started
January 2026
Primary completion
June 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ran Li
Guangdong Hengrui Pharmaceutical Co., Ltd
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.